The development of a novel mechanism therapeutic drug for rare intractable inflammatory diseases

2014 Fiscal Year Final Research Report

• Project/Area Number: 24249033
• Research Category: Grant-in-Aid for Scientific Research (A)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: Tohoku University
• Principal Investigator: MIYATA Toshio 東北大学, 医学(系)研究科(研究院), 教授 (10222332)
• Co-Investigator(Kenkyū-buntansha): DAN Takashi 東北大学, 医学系研究科, 准教授 (00512451)
• Co-Investigator(Renkei-kenkyūsha): ICHIMURA Atsuhiko 東北大学, 医学系研究科, 非常勤講師 (10609209)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 薬理学 / 生理活性 / 生体分子

Outline of Final Research Achievements

The study was performed to specify an adaptation of PAI-1 inhibitors which were effective and safe against rare intractable inflammatory diseases.
Finding bone marrow regeneration promoted by PAI-1 inhibitors in umbilical cord blood transplantation, led the doctor’s investigated phase 1 clinical trials. Non-clinical safety studies were carried out from the discovery of the efficacy in multiple sclerosis models.　Furthermore, as a result of PAI-1 inhibition in ovarian carcinoma cell lines, cell proliferation was suppressed by increasing the apoptosis and the G2/M phase cells. Moreover, the evaluation of the effects of PAI-1 inhibitors in bleomycin-induced lung fibrosis models, it was found that the lung hydroxyproline content was reduced significantly.

Free Research Field

医学（内科学）